ADMA Biologics Inc
ADMA Biologics develops, manufactures, and markets specialty plasma-derived biologics for immune deficiencies and infectious diseases. The company offers IVIG products BIVIGAM and ASCENIV, as well as Nabi-HB for Hepatitis B exposure. It also develops a pipeline of plasma-derived therapeutics and operates source plasma collection facilities. Products are sold through independent distributors, wholesalers, pharmacies, and alternate site providers.
Overview
Strengths
- Consistent growth: revenue has compounded at 60.9% a year over 6 years, rising every year.
- EBITDA margin of 39.4% beats 83% of its 128 Biotechnology peers (median 0.0%).
- Cheaper than its own history: P/E 20.6x vs. a historical average of 76.2x.
- Paying down debt: long-term debt fell by 3.7 percentage points of total assets last year.
Weaknesses
- Unreliable cash generation: free cash flow was negative in 4 of the last 7 years.
- Our discounted cash flow target price (5.92 USD) is 53% below the current price.
- Unstable profitability: operating margin ranged from -154% to 38% over the last 7 years, with operating losses in 4 of them.
- Earnings quality red flag: reported profit exceeds operating cash flow by 15.5% of total assets.
Key Financial Data